Today the Centers for Medicare & Medicaid Services (CMS) issued a final rule with comment to implement the Medicaid drug rebate provisions in the Affordable Care Act. The final regulation addresses key areas of Medicaid drug reimbursement and changes made to the Medicaid Drug Rebate Program by the Affordable Care Act. Among other things, this final rule ensures federal and state savings on Medicaid drug costs, establishes the long term framework for implementation of the Medicaid drug rebate pro with gram, and creates a more fair reimbursement system for Medicaid programs and pharmacies. In this final rule we also solicit additional comments on the definition of line extension drugs and the treatment of new formulations that we may consider addressing in future rule making.
For more information, including summaries of key provisions of the final rule, visit the Covered Outpatient Drugs Policy page on Medicaid.gov.
No hay comentarios:
Publicar un comentario